Alleged dumping of pharma raw material by Chinese firms, probe initiated
Advertisement
New Delhi: India has initiated a probe into the alleged dumping of a pharma raw material, Ceftriaxone Sodium Sterile, from China, following complaints by domestic manufacturers. Nectar Life Sciences and Sterile India have filed an application before the Commerce Ministry's investigation arm Directorate General of Trade Remedies (DGTR) seeking initiation of the probe.
According to a DGTR notification, the applicants have contended that material injury is being caused to the domestic industry due to dumped imports from China.
They requested imposition of anti-dumping duty on the import.
Ceftriaxone Sodium Sterile is an active pharmaceutical ingredient (API) or raw material used for formulation for treating disease like lower respiratory tract infection, skin infection, and intra-abdominal infection.
"On the basis of the duly substantiated written application by the domestic industry, and having satisfied itself, on the basis of the prima facie evidence submitted by the domestic industry, about dumping of the subject goods originating in or exported from the subject country (China)...the authority, hereby, initiates an investigation," it said.
Dumping impacts the price of the product in the importing country, hitting margins and profits of manufacturing firms.
According to global trade norms, a country is allowed to impose tariffs on such dumped products to provide a level-playing field to domestic manufacturers. The duty is imposed only after a thorough investigation by a quasi-judicial body, such as DGTR in India.
The imposition of anti-dumping duty is permissible under the World Trade Organization (WTO) regime. India and China are members of the Geneva-based organisation, which deals with global trade norms.
The duty is aimed at ensuring fair trading practices and creating a level-playing field for domestic producers vis-a-vis foreign producers and exporters.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.